Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study

Andersen, Vibeke; Egeberg, Rikke; Tjonneland, Anne; Vogel, Ulla Birgitte

Published in:
B M C Cancer

Link to article, DOI:
10.1186/1471-2407-12-183

Publication date:
2012

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Andersen, V., Egeberg, R., Tjonneland, A., & Vogel, U. B. (2012). Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study. B M C Cancer, 12. DOI: 10.1186/1471-2407-12-183
Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study

Vibeke Andersen¹²³⁷*, Rikke Egeberg⁴, Anne Tjønneland⁴ and Ulla Vogel⁵⁶

Abstract

Background: More than 50% of the colorectal cancer (CRC) etiology has been attributed to diet. Established or suspected dietary factors modifying risk of CRC are red meat, cereals, fish, and fibre. Diet and lifestyle may be linked to cancer through inflammation. Interleukin-10 (IL-10) is an anti-inflammatory cytokine. We wanted to test if dietary factors and IL10 polymorphisms interact in relation to colorectal carcinogenesis.

Methods: The functional IL10 polymorphism C-592A (rs1800872) and the marker rs3024505 were assessed in relation to diet and lifestyle in a nested case-cohort study of 378 CRC cases and 775 randomly selected participants from a prospective study of 57,053 persons. Genotyping data on the IL10 polymorphism C-592A, smoking and non-steroidal anti-inflammatory drugs (NSAID) was retrieved from Vogel et al. (Mutat Res, 2007; 624:88). Incidence rate ratios (IRR) and 95% Confidence Interval (95% CI) were calculated.

Results: No associations were found between the IL10 rs3024505 polymorphism and risk of CRC. There was interaction between rs3024505 and dietary fibre (P-value for interaction = 0.01). IL10 rs3024505 homozygous wildtype carriers were at 27% reduced risk of CRC per 10 g fibre per day (95% CI: 0.60-0.88) whereas variant carriers had no risk reduction by fibre intake. Also, interaction between IL10 C-592A and intake of fibre was found (P-value for interaction = 0.02). Among those eating <17.0 grams of fibre per day, carriers of an C-592A variant allele had a statistically significantly higher risk of colorectal cancer compared to homozygous wildtypes. No significant differences in colorectal cancer risk were observed between the reference group (CC and <17.0 g/day) and carriers of one C-592A variant allele eating 17.0 or more grams of dietary fibre per day. This suggests that the increased risk due to carrying the variant allele can be overcome by higher fibre intake. No interactions between IL10 polymorphisms and dietary meat, cereal, or fish intake, or between IL10 rs3024505 and smoking or NSAID use were found.

Conclusions: In this northern Caucasian cohort we found interaction between IL10 and dietary fibre in CRC carcinogenesis. High intake of fibre seems to protect against CRC among individuals with IL10 related genetic susceptibility to CRC. This finding should be evaluated in other prospective and population-based cohorts with different ethnic groups.

Keywords: Gene-environment interaction, Dietary fibre, Fibers, Inflammation, Red and processed meat, Cereals, Fish, Carcinogenesis, Cohort, Prospective study, Population-based, Epidemiology, Smoking, NSAID

* Correspondence: vandersen@health.sdu.dk
¹Medical Department, SHS Aabenraa, DK-6200, Aabenraa, Denmark
²Institute of Regional Health Service Research, University of Southern Denmark, 5230, Odense, Denmark
Full list of author information is available at the end of the article

© 2012 Andersen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Colorectal cancer (CRC) constitutes the second most common cancer in the Western World [1] and the burden of the disease is expected to increase dramatically due to demographic trends and implementation of westernized lifestyle in developing countries [2]. More than 50% of the CRC etiology has been attributed to diet and lifestyle [1,3] and, therefore, may be potentially avoidable by modification of these factors [4].

A modified inflammatory response may be an intermediate between diet and lifestyle on one hand and CRC on the other. Suspected dietary risk factors for CRC are red meat, dietary fibre, cereals and fish [4,5]. In a recent review, both intake of red meat and processed meat was linked to higher risk of CRC (summary effect estimate of 1.28 (95% CI: 1.18-1.39) per 120 g red meat/day and 1.21 (95% CI: 1.04-1.42) per 50 g processed meat per day) [6]. Meat represents sources of pro-inflammatory n-6 polyunsaturated fatty acids (PUFA), heterocyclic amines (HCA) and polycyclic aromatic hydrocarbons (PAH) formed during cooking at high temperature, haem iron and N-nitroso compounds [6], which may potentiate intestinal inflammation [7]. Dietary fibre were found to protect against CRC (adjusted relative risk 0.75 (95% CI: 0.59-0.95) for the highest versus lowest quintile of intake) [5]. Fibre are converted by colonic bacteria to short-chain fatty acids including butyrate which has been found to have anti-inflammatory properties [8]. Also cereal fibre has been shown to protect against colon cancer [9]. High fish intake has been found to protect against CRC [10,11] and fish is a source of anti-inflammatory n-3 PUFA [12]. Smoking has been reported to confer risk of CRC [13,14] and the mechanism may include induction of inflammation [15]. Long term use of non-steroidal anti-inflammatory drugs (NSAID) has been found to confer protection against CRC presumably by lowering an inflammatory response in colon [16,17].

Long term chronic inflammation is a well-established risk factor for CRC. Interleukin 10 (IL-10) [18,19] is an anti-inflammatory cytokine and crucial for maintaining intestinal homeostasis [20]. Animal studies suggest that insufficient IL-10 function promotes intestinal inflammation and CRC [21,22]. The biological mechanisms of action of IL-10 in the intestinal epithelium may involve blocking of the endoplasmic reticulum (ER) stress response (via inhibition of the ER activating transcription factor (ATF)-6 to the GRP78 promoter) [23] and, furthermore, inhibition of nuclear factor-κB (NFκB) activation (via stabilisation of inhibitory-κB (IκB)) [24]. Diet and lifestyle may directly or indirectly affect IL-10 function. For example, in animal models, mucosal IL-10 production has been found to be stimulated by intestinal microbes [25,26] which, on the other hand, have been found to be affected by diet and NSAID use [27,28]. Also, studies on isolated leukocytes showed that fatty acids stimulate the production of IL-10 [29].

Investigating functional genetic variants in carefully selected candidate genes in combination with diet and lifestyle factors in well-characterized prospectively collected study populations has previously been successfully applied for the study of underlying carcinogenic mechanisms of foods items [30-32]. The functional IL10 promoter polymorphisms G-1082A, C-819 T, and C-592A are in tight linkage disequilibrium. The haplotype encompassing all three variant polymorphisms is associated with low IL-10 protein production in lymphocytes in vitro [33] and in vivo [34,35] probably because the A allele of the IL10 promoter polymorphism C-592A leads to the formation of a binding site for the ETS family of transcription factors [36]. An association between the low activity-associated IL10 C-592A and IL10 G-1082A variant genotypes and high risk of CRC has been found in some case–control studies [37-39] but not all [40]. Another polymorphism, the marker rs3024505 immediately downstream of the IL10 gene, has not been investigated in relation to CRC but has been associated with risk of inflammatory bowel disease [41,42].

Hence, in search for a biological understanding, we hypothesized that dietary components and lifestyle may modify CRC risk through modifying the inflammatory response in colon by modifying IL-10 expression. An interaction between functional polymorphisms in IL10 and diet would indicate that IL-10 and hence the inflammatory response is implicated in the pathway leading from the dietary component to CRC. We therefore investigated the interaction between the functional polymorphism IL10 C-592A and the marker rs3024505 and diet, and between rs3024505 and smoking and NSAID use in relation to development of CRC in a case-cohort study of 378 CRC cases and 775 randomly selected participants from the prospective population-based Danish Diet, Cancer and Health study.

Methods

Studied subjects

Diet, Cancer and Health is an ongoing Danish cohort study designed to investigate the relation between diet, lifestyle and cancer risk [43]. The cohort consists of 57,053 persons, recruited between December 1993 and May 1997. All the subjects were born in Denmark, and the individuals were 50 to 64 years of age and had no previous cancers at study entry. Blood samples and questionnaire data on diet and lifestyle were collected on study entry.

Follow-up and endpoints

Follow-up was based on population-based cancer registers. Between 1994 and 2003, 405 CRC cases (184
women and 221 men) were diagnosed. A subcohort of 810 persons (368 women and 442 men) were randomly selected within the cohort [38,43]. Blood samples were available for 397 cases and 800 subcohort members. All information on genotypes and diet and lifestyle factors was available for 378 cases and 775 subcohort members (44 with missing genotype data and 18 with missing diet and/or lifestyle data were excluded).

Dietary and lifestyle questionnaire

Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socioeconomic factors were collected at enrolment.

In the food-frequency questionnaire, diet consumption was assessed in 12 categories of predefined responses, ranking from ‘never’ to eight times or more per day. The daily intake was then calculated by using FoodCalc [44]; this program uses population specific standardized recipes and portion sizes. Intake of red meat in grams per day was calculated by adding up intake of beef, veal, pork, lamb and offal. Intake of processed meat in grams per day was calculated by adding up intake of processed red meat, including bacon, smoked ham, salami, frankfurter, Cumberland sausage, cold cuts and liver pâté.

Dietary fibre intake were based on country-specific food composition tables, which were reviewed to ensure comparability to the association of official analytical chemists (AOAC) fibre definition, which includes lignin and resistant starch [45]. Fibre intake is calculated by multiplying the frequency of consumption of relevant foods by their fibre content as determined from national databases of food content [46].

Contributing food items to the food group ‘cereals’ included wholegrain foods (wholegrain bread, rye bread, wholegrain flour, oatmeal, corncobs, müsli, and crisp-bread) and refined grain foods (white wheat bread, wheat flour, rice flour, potato flour, corn flour/starch, pasta, wheat) and was measured in grams per day [47].

Intake of ‘fish’ in grams per day was calculated by adding up intake of fresh and processed fish.

The questionnaire was tested in a pilot study preceding the Diet, Cancer and Health study. Pearson correlation coefficients (adjusted for total energy intake) illustrating the comparison of nutrient scores estimated from the food-frequency questionnaire and from weighed diet records were 0.39 and 0.53 for dietary fibre and 0.37 and 0.14 for meat for men and women, respectively [48,49].

Smoking status was classified as never, past or current.

The lifestyle questionnaire included this question regarding use of NSAID: “Have you taken more than one pain relieving pill per month during the last year?” If the answer was yes, the participant was asked to record how frequently they took each of the following medications: “Aspirin”, “Paracetamol”, “Ibuprofen”, or “Other pain relievers”. The latter category included NSAID preparations other than aspirin and ibuprofen. Based on all records, we classified study subjects according to use of “any NSAID” (≥ 2 pills per month during one year) at baseline.

Genotyping

Buffy coat preparations were stored at minus 150°C until use. DNA was extracted as described [50]. Genotyping was performed in 5 ul reactions containing 2.5 ul mastermix (Applied Biosystems), ca 20 ng DNA and 1 mM primers and 100 nM probes or 1 x predeveloped assay. IL10 rs3024505 were determined using the pre-developed allelic discrimination assay C_15869717_10 (Applied Biosystems). C-592A (rs1800872) was determined and reported previously [38]. Primers were: Forward: 5′-GGTAAAGGAGCC TGGAACACATC-3′, Reverse: 5′-CCAAGCGAGCCCT CCATTTC-3′ and probes were: A-allele: 5′-VIC-ACCCCGC CTGTACTGAGGAAC-TAMRA-3′ and C-allele: FAM- ACCCGCTGTCTCCTGAGGAAC-TAMRA-3′ [51].

Laboratory staff was blinded to case/control status during analysis. Known genotype controls were included in each run. To confirm reproducibility, genotyping was repeated for 10% of the samples yielding 100% identity.

Statistical analysis

Hardy-Weinberg equilibrium was determined manually by the χ²-test.

The analyses were performed according to the principles for the analysis of case-cohort studies [52]. The analyses were performed unweighted. Age was used as the time scale in the Cox regression model. Tests and confidence intervals were based on Wald’s test using the robust estimate of the variance-covariance matrix for the regression parameters in the Cox regression model [53].

All models were adjusted for baseline values of suspected risk factors for colorectal cancer such as body mass index (BMI) (kg/m², continuous), NSAID (yes/no), use of hormone replacement therapy (HRT) (never/past/current, among women), smoking status (never/past/current), intake of dietary fibre (g/day, continuous), and red meat and processed meat (g/day, continuous).

The likelihood ratio test was used for interaction analyses between the two IL10 polymorphisms and intake of meat, dietary fibre, cereals, fish, and between rs3024505 and smoking status and NSAID use. In interaction analyses between IL10 polymorphisms and dietary fibre intake entered as a categorical variable, tertile cutpoints were based on the distribution among cases. Trend test were calculated using the Wald test.

All analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC).

A p < 0.05 was considered to be significant.
Ethics

All participants gave verbal and written informed consent. The study was approved by the regional Ethics Committees on Human Studies (Jr.nr. (KF)11-037/01 and Jr nr. (KF)01-045/93), and the Danish Data Protection Agency.

Results

Characteristics of the study population and risk factors for CRC are shown in Table 1. There were significant differences in baseline characteristics between the cases and subcohort members for age and intake of fibre (Table 1). The genotype distribution of the polymorphisms in the subcohort did not deviate from Hardy-Weinberg equilibrium (results not shown). The variant allele frequency for IL10 rs3024505 and C-592A were 0.16 and 0.22, respectively, in the subcohort.

Associations between polymorphisms and CRC

There was no association between IL10 rs3024505 genotypes and CRC risk (Table 2). C-592A was genotyped and the association to risk of CRC was reported previously [38]. Since we observed no gene-dose effects, variant genotypes were combined in the interaction analysis to maximize the statistical power. Haplotype distribution among the controls showed no linkage between the two polymorphisms and therefore haplotype analysis was not performed.

Gene-environmental analyses

There was interaction between rs3024505 and intake of dietary fibre (P-value for interaction = 0.01) (Table 3). IL10 rs3024505 homozygous wildtype carriers were at 27% reduced risk of CRC per 10 g fibre per day (95% CI: 0.60-0.88) whereas variant carriers had no risk reduction by fibre intake. C-592A variant allele carriers were at reduced risk of CRC by fibre intake (IRR pr 10 g fibre/day: 0.71 (0.54-0.93)) whereas homozygous wildtype allele carriers were not (IRR pr 10 g/day: 0.90 (0.74-1.09)). There was however no statistically significant interaction between genotype and fibre intake (P-value for interaction = 0.15) (Table 3). No statistically significant

| Table 1 Baseline characteristics of study population selected for the diet, cancer and health cohort |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Cases** | **Subcohort** | **P-value** |
| **No. (%)** | **Medians (5-95%)** | **No. (%)** | **Medians (5-95%)** | **P-value** |
| Total | 378 (100) | 775 (100) | | | |
| Sex | | | | | |
| Men | 211 (33) | 422 (67) | | | |
| Women | 167 (32) | 353 (68) | | | |
| Age at inclusion (years) | 58 (51–64) | 66 (50–64) | <0.0001 | | |
| BMI (kg/m²) | 26 (21–34) | 26 (20–33) | 0.06 | | |
| Food intake (g/day) | | | | | |
| Alcohol¹ | 15 (1–68) | 13 (1–63) | 0.05 | | |
| Dietary fibre | 20 (10–31) | 21 (11–35) | 0.001 | | |
| Red and processed meat | 111 (50–240) | 109 (40–239) | 0.73 | | |
| Smoking status | | | | | |
| Never | 118 (31) | 261 (34) | | | |
| Past | 115 (30) | 245 (32) | | | |
| Current | 145 (38) | 269 (35) | | | |
| NSAID use | | | 0.53 | | |
| No | 255 (67) | 537 (69) | | | |
| Yes | 123 (33) | 238 (31) | | | |
| HRT use among women | | | 0.71 | | |
| Never | 97 (26) | 187 (24) | | | |
| Past | 26 (7) | 61 (8) | | | |
| Current | 44 (12) | 105 (14) | | | |

¹ Among current drinkers.
interactions between IL10 polymorphisms and dietary meat, cereals, or fish intake were found (Table 3).

Because of the interaction between rs3024505 and intake of dietary fibre, tertile analysis of fibre intake and genotype in relation to CRC was performed to obtain more information about the association of the studied polymorphisms in absence of fibre intake. Among those eating < 17.0 grams of fibre per day, carriers of the C-592A variant allele had a statistically significantly increased risk of colorectal cancer compared to homozygous wildtype carriers. Interestingly, no significant differences in CRC risk were observed between the reference group (CC and < 17.0 g/day) and carriers of the C-592A variant allele eating 17.0 or more grams of dietary fibre per day (Table 4). This suggests that the increase in risk associated with carrying the variant allele could be overcome by higher fibre intake.

When the two genotypes were combined, fibre intake was associated with the most protective effect among homozygous wildtype carriers of rs3024505 who were variant allele carriers of C-592A (IRR = 0.55; 95% CI: 0.35-0.86) (Table 5). The observed pattern suggested additive effects of the two polymorphisms and there was no statistically significant interaction (P-value for interaction = 0.19).

No statistically significant interactions between IL10 rs3024505 polymorphism and smoking (results not shown) or NSAID use (results not shown) was found in relation to CRC.

The protective effect of dietary fibre on risk of CRC is well documented [5]. To our knowledge, this is the first study which suggests that the protective effect of dietary fibre may involve an interaction with anti-inflammatory regulation. fibre are the indigestible portion of plant foods whereof the soluble fibre are fermented by bacteria in the digestive tract and the insoluble fibre have bulking action. Of particular interest, dietary intake of starch have been found to impact the composition of the gut microbiota [54]. Commensal bacteria such as Clostridia-related species and Bacteroides fragilis have been shown to affect host IL-10 responses and result in enhanced resistance to intestinal infection in mouse models [55-58]. Similarly, increased IL-10 level in blood was found after 4 weeks intake of dietary fibre in overweight humans [59]. Our results support the notion of biological interaction between fibre intake and host IL-10 synthesis. Furthermore, our results suggest this has beneficial effects in individuals carrying the C-592A variant allele and/or two alleles of rs3024505.

A case–control study of 495 gastric cancer (GC) cases and 495 controls found no interaction between smoking and IL10 genotypes [60]. Both carriers of the C-592A homozygous wildtype genotype and carriers of the variant genotypes had high risk of GC among smokers (odds ratio (OR) 2.88 (95% CI: 1.67-4.95) and 2.06 (95% CI: 1.20-3.55), respectively) compared to the non-smoking reference group.

### Table 2 Incidence rate ratios and 95% confidence intervals for the studied IL10 gene polymorphisms in the diet, cancer and health study

| rs3024505 | N_Case | N_Subcohort | Crude IRR (95% CI)a | Adjusted IRR (95% CI)b | P-valuec |
|-----------|--------|-------------|---------------------|------------------------|----------|
| CC        | 268    | 553         | 1.00                | 1.00                   | -        |
| CT        | 99     | 202         | 0.99 (0.79-1.25)    | 1.01 (0.80-1.28)       | 0.91     |
| TT        | 11     | 20          | 1.15 (0.63-2.10)    | 1.11 (0.61-2.03)       | 0.73     |
| CT and TT | 110    | 222         | 1.01 (0.81-1.26)    | 1.02 (0.82-1.28)       | 0.85     |

C-592A (rs1800872)d

| CC        | 238    | 470         | 1.00                | 1.00                   | -        |
| AC        | 116    | 261         | 0.91 (0.73-1.14)    | 0.90 (0.72-1.12)       | 0.36     |
| AA        | 24     | 44          | 1.11 (0.74-1.67)    | 1.10 (0.73-1.65)       | 0.65     |
| AC and AA | 140    | 305         | 0.94 (0.77-1.16)    | 0.93 (0.76-1.14)       | 0.50     |

| **Note:** a Crude analyses. b Analyses adjusted for smoking status, alcohol, HRT status (women only), BMI, use of NSAID, and intake of red and processed meat and dietary fibre. c P-value for the adjusted estimates. d Data for IL10 rs1800872 were taken from (38).
### Table 3 Interaction between dietary factors and the studied IL10 polymorphisms in relation to colorectal cancer risk

|                      | Crude IRR (95% CI)\(^a\) | Adjusted IRR (95% CI)\(^b\) | P\(^c\) Interaction |
|----------------------|---------------------------|-----------------------------|---------------------|
| **Intake of red and processed meat (per 25 g/day)** |                           |                             |                     |
| rs3024505            |                           |                             |                     |
| CC                   | 1.02 (0.96-1.07)          | 1.02 (0.96-1.08)            | 0.78                |
| CT and TT            | 1.02 (0.96-1.09)          | 1.03 (0.96-1.10)            |                     |
| C-592A (rs1800872)   |                           |                             |                     |
| CC                   | 1.01 (0.96-1.06)          | 1.02 (0.97-1.07)            | 0.92                |
| AC and AA            | 1.03 (0.96-1.11)          | 1.02 (0.95-1.11)            |                     |
| **Intake of dietary fibre (per 10 g/day)**        |                           |                             |                     |
| rs3024505            |                           |                             |                     |
| CC                   | 0.70 (0.59-0.84)          | 0.73 (0.60-0.88)            |                     |
| CT and TT            | 1.10 (0.83-1.46)          | 1.12 (0.84-1.49)            | 0.01                |
| C-592A (rs1800872)   |                           |                             |                     |
| CC                   | 0.88 (0.73-1.06)          | 0.90 (0.74-1.09)            |                     |
| AC and AA            | 0.67 (0.51-0.88)          | 0.71 (0.54-0.93)            | 0.15                |
| **Intake of cereals (per 50 g/day)**              |                           |                             |                     |
| rs3024505            |                           |                             |                     |
| CC                   | 0.89 (0.82-0.97)          | 0.99 (0.88-1.12)            |                     |
| CT and TT            | 1.03 (0.91-1.16)          | 1.13 (0.98-1.30)            | 0.09                |
| C-592A (rs1800872)   |                           |                             |                     |
| CC                   | 0.95 (0.87-1.04)          | 1.05 (0.93-1.18)            |                     |
| AC and AA            | 0.91 (0.81-1.02)          | 1.01 (0.88-1.16)            | 0.63                |
| **Intake of fish (per 25 g/day)**                 |                           |                             |                     |
| rs3024505            |                           |                             |                     |
| CC                   | 0.88 (0.78-1.00)          | 0.89 (0.79-1.01)            |                     |
| CT and TT            | 0.95 (0.76-1.20)          | 0.97 (0.77-1.24)            | 0.51                |
| C-592A (rs1800872)   |                           |                             |                     |
| CC                   | 0.85 (0.74-0.97)          | 0.85 (0.74-0.98)            |                     |
| AC and AA            | 1.01 (0.84-1.21)          | 1.03 (0.86-1.24)            | 0.09                |

**\(^a\)** Crude analysis.

**\(^b\)** Analysis adjusted for smoking status, alcohol, HRT status (women only), BMI, use of NSAID, and intake of red and processed meat and dietary fibre.

**\(^c\)** P-value for interaction between polymorphisms and dietary factors for the adjusted estimates.

### Table 4 Incidence rate ratio (IRR) for colorectal cancer for tertiles of intake of dietary fibre by IL10 polymorphisms among cases (Nc) and subcohort (Ns)

|                      | Nc  | Ns  | Nc  | Ns  | Intake tertiles (g/day) | IRR (95% CI)\(^a\) |
|----------------------|-----|-----|-----|-----|--------------------------|---------------------|
|                      |     |     |     |     | <17.0                    |                     |
| rs3024505            |     |     |     |     | 17.0-22.7                |                     |
|                      |     |     |     |     | >22.7                    |                     |
|                      |     |     |     |     | P\(^b\) Int              |                     |
| CC                   | 96  | 152 | 86  | 176 | 86  | 225 | 1.00 | 0.87 (0.65-1.16) | 0.73 (0.55-0.98) | 1.00 | 0.87 (0.65-1.16) | 0.73 (0.55-0.98) | 1.00 | 0.87 (0.65-1.16) | 0.73 (0.55-0.98) |
| CT and TT            | 28  | 56  | 39  | 82  | 43  | 84  | 0.83 (0.54-1.27) | 0.83 (0.58-1.18) | 0.96 (0.66-1.38) | 0.16 |
| C-592A (rs1800872)   |     |     |     |     |     |     |                     |                     |                     |
| CC                   | 69  | 137 | 81  | 148 | 88  | 185 | 1.00 | 1.17 (0.84-1.61) | 1.08 (0.78-1.49) | 1.00 | 1.17 (0.84-1.61) | 1.08 (0.78-1.49) | 1.00 | 1.17 (0.84-1.61) | 1.08 (0.78-1.49) |
| AC and AA            | 55  | 71  | 44  | 110 | 41  | 124 | 1.44 (1.02-2.05) | 0.87 (0.59-1.27) | 0.80 (0.54-1.19) | 0.02 |

**\(^a\)** Analysis adjusted for smoking status, alcohol, HRT status (women only), BMI, use of NSAID, and intake of red and processed meat.

**\(^b\)** P-value for interaction between polymorphisms and dietary factors for the adjusted estimates.
The present study found no association between *IL10* rs3024505 polymorphism and risk of CRC. This polymorphism is a marker polymorphism with no known function which has been associated with IBD but which has not been studied in relation to CRC [41,42]. Associations between the low activity-associated *IL10* C-592A and *IL10* rs1800896 variant genotypes and high risk of CRC have been found by some case-control studies [37-39] but not all [40]. Thus, carriers of the C-592A homozygous variant genotype were at high risk of CRC compared to the homozygous wildtype carriers in the studies by Čacev et al. and Vogel et al. (odds ratio (OR) of 4.07 (95% CI: 1.28-12.96) and OR 1.25 (95% CI: 0.72-2.18), respectively) [37,38]. *IL10* has been studied in relation to other cancers, including gastrointestinal cancers [61-66], however, the results have been ambiguous. *IL10* has not been associated with CRC in GWAS [67,68]. Our study suggests that intake of fibers may play a role in individuals carrying the C-592A variant allele and in individuals carrying the rs3024505 homozygous wildtype genotype. In the combination analysis of the two polymorphisms, additive effects were found, suggesting that both polymorphisms contribute to the found effects. Our results suggest that *IL10* polymorphisms may be most important in populations with low fibre intake.

This study used a nested case-cohort design which is efficient and has the major advantage that data and samples were collected before diagnosis. A main strength of our study is a well-characterized study population. Information on diet and lifestyle factors was collected at enrolment for all participants which minimizes the risk of differential misclassification of cases and comparison group. However, data were only collected once, and may thus not be representative for the lifestyle during follow-up. This is, however, not expected to result in differential misclassification. Furthermore, information on food intake was based on a semi-quantitatively food frequency questionnaire [43,49], which was evaluated and found usable [48]. In addition, the results were adjusted for known confounding factors affecting the risk of CRC in this cohort including dietary factors, body mass index (BMI), alcohol, smoking status and NSAID use. Cases were generally older than the comparison group at inclusion into the Diet, Cancer and Health cohort. This is because the comparison group was chosen as a random sample of the study cohort, whereas cases were defined by their age at diagnosis. However, care was taken to ensure that all risk estimates were age adjusted and this means that we generally had longer follow up on the members of the comparison group than of the cases, because the CRC cancer cases generally belonged to the older age fraction of the recruited persons. Fibre intake was lower among the cases compared to controls. To prevent confounding, all risk estimates were adjusted for fibre intake. A main limitation of the study is the limited sample size.

A power calculation showed that we had 82% chance of detecting an OR of 1.5 [69]. Therefore, since no gene dose effects were observed, heterozygous and homozygous variant genotype carriers were combined for the analyses of interactions to obtain sufficient statistical power. Nevertheless, in the light of the obtained P-values and the number of statistical tests performed, we cannot exclude that our positive findings may be due to chance. Moreover, we cannot exclude that associations and/or interactions may not have been identified due to insufficient power.

The present result is in agreement with previous studies proving the concept that gene-environmental interactions may be utilized for identification of underlying biological pathways in carcinogenesis [31,32]. The mentioned studies suggested that the intestinal transporter ABCB1 and nuclear factor kappa B (NFκB) are involved in meat carcinogens.

**Conclusions**

This study of a Northern Caucasian cohort suggests interaction between *IL10* and dietary fibre in CRC carcinogenesis. High intake of fibre seems to protect against CRC among individuals with *IL10* related genetic susceptibility.
to CRC. This finding should be evaluated in other prospective population-based cohorts where information on fibre intake is available.

Abbreviations
BMI: Body mass index; CRC: Colorectal cancer; HRT: Hormone replacement therapy; NSAID: Non-steroidal anti-inflammatory drugs; IL-10: Interleukin 10; CI: Confidence interval; IRR: Incidence rate ratio.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
VA and UV designed the molecular genetic studies, UV determined the genotypes and VA drafted the manuscript. AT designed the cohort and RE performed the statistical analysis. VA and UV conceived of the study, its design and coordination. All authors helped to draft the manuscript, read and approved the final manuscript.

Acknowledgements
Lars Bentsen is acknowledged for technical assistance. We thank the staff at the Library, Viborg Regional Hospital. This work was supported by “Familien Erichsens Mindefond”, The Lundbeck Foundation, “Jøhs M Klein og Hustrus mindelegat”, “Agnette Løvgreenes Legat”, “Jag og Olga Madsens Fond”, the Danish Cancer Society, grant DP00027, the grant ENGAGE from the Novo Erichsens Mindefond Viborg, Denmark. 4Danish Cancer Society Research Center, DK-2100, Technical University of Denmark, DK-2860, Soborg, Denmark. 7Medical Odense, Denmark. 3Medical Department, Viborg Regional Hospital, DK-8800, Denmark. The Lundbeck Foundation, Viborg Regional Hospital. This work was supported by the Danish Cancer Society, grant DP00027, the grant ENGAGE from the Novo Erichsens Mindefond Viborg, Denmark. This work was supported by the Danish Cancer Society, grant DP00027, the grant ENGAGE from the Novo Erichsens Mindefond Viborg, Denmark.

Published: 17 May 2012

References
1. Huxley RR, nasy-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009, 125:171–180.
2. Karsa LV, Lagnier- Patrick J, Lambert R, Vauget C. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol 2010, 24:381–396.
3. Johnson IT. New approaches to the role of diet in the prevention of cancers of the alimentary tract. Mutat Res 2004, 551:9–28.
4. World Cancer Research Fund/American Institute for Cancer Research. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC); an observational study. Lancet 2003, 361:1496–1501.
5. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, et al. Dietary intake is available.
6. Polypeptide food additives, 4-aminobiphenyl-haemoglobin adducts and diet in the European Prospective Investigation into Cancer and Nutrition (EPIC) prospective study. Br J Nutr 2008, 100:489–495.
7. Hansen L, Sieie G, Landberg R, Lund E, Palmqvist R, Johansson L, et al. Intake of dietary fiber, especially from cereal foods, is associated with lower incidence of colon cancer in the HELGA cohort. Int J Cancer 2011, 10.
8. Gonzalez CA, Riboli E. Diet and cancer prevention: where we are, where we are going. Nutr Cancer 2006, 56:225–231.
9. Gonzalez CA. The European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2006, 9:124–126.
10. Joensen AM, Schmidt EB, Dethlefsen C, Johnsen SP, Tjonneland A, Rasmussen LH, et al. Dietary intake of total marine n-3 polysaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid and the risk of acute coronary syndrome - a cohort study. Br J Nutr 2010, 103:602–607.
11. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer 2009, 124:2406–2415.
12. Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ. Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2009, 7:682–688.
13. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation 2005, 112:941–945.
14. Fries S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, et al. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control 2009, 20:731–740.
15. Fossom E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603–1613.
16. Ouyang W, Rutz S, Cereill NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011, 29:117–119.
17. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010, 21:331–344.
18. Battaglia M, Gianfani C, Gregori S, Roncarolo MG. IL-10 producing T regulatory type 1 cells and oral tolerance. Ann N Y Acad Sci 2004, 1029:142–53.
19. Ermdan SE, Rao VP, Poualtidh T, Thirg MM, Ge Z, Feng Y, et al. CD4(+)CD25 (+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 2003, 63:6504–6505.
20. Westbrook MA, Szakmany A, Schieltz RH. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res 2010, 705:40–59.
21. Shioada A, Ruza PA, Daniel H, Kim SC, Rogler G, Sartor RB, et al. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells. Impact on chronic inflammation. Gastroenterology 2007, 132:190–207.
22. Al-Ashry R, Chakroun I, El-Sabban ME, Horafran DA. The role of NF-kappaB in mediating the anti-inflammatory effects of IL-10 in intestinal epithelial cells. Cytokine 2006, 36:1–8.
23. Duell BL, Tuck CK, Carey AJ, Wu F, Cripps AW, Ulett GC. Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol 2012, 65:995X.
24. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2006, 443:620–625.
25. Thomas F, Hehemann JH, Rebuffet E, Czjzek M, Michel G. Environmental and gut bacterioites: the food connection, Front Microbiol 2011, 2:293.
26. Zhu Y, Michelle LT, Jabin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011, 309:119–127.
27. Vinolo MA, Rodrigues HG, Nachbar RT, Cun R. Regulation of inflammation by short chain fatty acids. Nutrients 2011, 3:558–616.
28. Andersen V, Christensen J, Overvad K, Tjonneland A, Vogel U. Human colorectal cancer: a Danish prospective study. Eur J Gastroenterol Hepatol 2011, 23:282–9.
29. Andersen V, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer 2010, 10:464.
30. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) gene and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 2009, 9:407.
31. Turner DM, Williams DM, Sankaran D, Lazarus M, Srinott PJ, Hutchinson M. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1–8.
34. Yilmaz V, Yentur SP, Saruhan-Direskeneli G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine 2005; 30:188–194.
35. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson L, Woo P. Polymorphic haplotypes of the interleukin-10 S' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42:1101–1108.
36. Shin HD, Winkler C, Stephens JC, Beamer J, Young H, Goedert JJ, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97(14):14467–14472.
37. Cacev T, Radosavic S, Krizanac S, Kapitanovic S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2009; 28:1572–1580.
38. Vogel U, Christensen J, Dypdahl M, Fris S, Hansen RD, Wallin H, et al. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 2007; 624:88–100.
39. Tsilidis KK, Hetszloer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. Association of common polymorphisms in IL10 and, in other genes, with colorectal cancer. Cancer Causes Control 2009; 20:1739–1751.
40. Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altiere A, et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 2008; 29:1202–1206.
41. Franke A, Balshchuk T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008; 40:1319–1322.
42. Andersen V, Ernst A, Christensen J, Ostergaard M, Jacobsen BA, Tjonneland A, et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohn’s disease in a Danish case–control study. BMC Med Genet 2010; 11:82.
43. Tjonneland A, Olsen A, Boll K, Kristensen T, Engholm G, et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 2007; 35:432–441.
44. Foodcalc 1.3. Computer program 1998. 2009. http://www.foodcalc.dk.
45. Slomani N, Dehaveng G, Unwin I, Southgate DA, Vignat J, Screxh G, et al. The EPIC nutrient database project (ENDB): a first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. Eur J Clin Nutr 2007; 61:1037–1056.
46. Prosky L, Asp NG, Furda I, De Vries JW, Schweizer TF, Harland BF. Determination of total dietary fiber in foods and food products: collaborative study. J Assoc Off Anal Chem 1985; 68:677–679.
47. Slomani N, Kaakki K, Ferran P, Caparogna C, Clavel-Chapelon F, Lattez G, et al. European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study: rationale, design and population characteristics. Public Health Nutr 2002; 5:1125–1145.
48. Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM. Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol 1991; 20:906–912.
49. Tjonneland A, Haraldsdottir J, Overvad K, Stripp C, Ewertz M, Jensen OM. Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. Int J Epidemiol 1992; 21:770–777.
50. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:231.
51. Macfarlane TH, Sharp L, Hold GL, Little J, El-Omir EI. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 2005; 14:1613–1618.
52. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52:1165–1172.
53. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994; 50:1064–1072.
54. Walker AW, Ince J, Duncan SH, Webster LM, Holtop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011; 5:220–230.
55. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010; 330:1768–1773.